Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CHRS stock hub

Coherus Oncology, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CHRSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

269.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CHRS

In the news

Latest news · CHRS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/E1.6

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-78.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CHRS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

222

Groups with data

Currency

USD

Showing 222 of 222 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001512762
Company name	Coherus Oncology, Inc.
Country	United States
Country code	US
Cusip	19249H103
Employees	147
Employees Change	-81%
Employees Change Percent	-35.53
Enterprise value	$152.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2014-11-06
Isin	US19249H1032
Last refreshed	2026-05-10
Market cap	$269.9M
Market cap category	Micro-Cap
Price	$1.75
Price currency	USD
Rev Per Employee	286,884.35x
Sector	Healthcare
Sic	2836
Symbol	CHRS
Website	https://www.coherus.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	62.26%
EV Earnings	0.91x
EV Sales Forward	1.97x
EV/Sales	3.61x
FCF yield	-51.32%
P/B ratio	3.47x
P/E ratio	1.61x
P/S ratio	6.4x
PS Forward	3.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	67.24%
Gross Profit	$28.4M
Gross Profit Growth	60.56%
Gross Profit Growth Q	74.65%
Gross Profit Growth3 Y	-41.4%
Gross Profit Growth5 Y	-42.16%
Net Income	$168M
Net Income Growth	489.41%
Net Income Growth Quarters	1%
Net Income Growth Years	3%
Net Income Growth5 Y	4.91%
Pretax Margin	-434.23%
Profit Margin	398.43%
Profit Per Employee	$1.1M
Profitable Years	2
ROA	-31.2
Roa5y	-24.85
ROCE	-149.6
ROIC	-78.2

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-21.31%
Cagr1y	85.03%
Cagr3y	-38.1%
Cagr5y	-34.33%
EPS Growth	476.4
EPS Growth Quarters	1
EPS Growth Years	4
EPS Growth5 Y	-2.45
Revenue Growth	59.81x
Revenue Growth Q	64.85x
Revenue Growth Quarters	2x
Revenue Growth Years	1x
Revenue Growth3 Y	-41.54x
Revenue Growth5 Y	-38.41x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.12
Assets	$258.3M
Cash	$172.1M
Current Assets	$206.7M
Current Liabilities	$140.4M
Debt	$54.4M
Debt Equity	$0.89
Equity	$61M
Interest Coverage	-19.6
Liabilities	$197.3M
Long Term Assets	$51.6M
Long Term Liabilities	$56.9M
Net Cash	$117.8M
Net Cash By Market Cap	$43.63
Net Debt Equity	$-1.93
Tangible Book Value	$14.8M
Tangible Book Value Per Share	$0.12
WACC	10.39

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.47
Inventory Turnover	3.74
Net Working Capital	$-104M
Quick ratio	1.36
Working Capital	$66.3M
Working Capital Turnover	$0.68

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-90.89%
1Y total return	84.95%
200-day SMA	1.53
3Y total return	-76.29%
50-day SMA	1.74
50-day SMA vs 200-day SMA	50over200
5Y total return	-87.78%
All Time High	38.1
All Time High Change	-95.41%
All Time High Date	2015-07-22
All Time Low	0.66
All Time Low Change	165.03%
All Time Low Date	2024-11-05
ATR	0.1
Beta	1.02
Beta1y	1.41
Beta2y	1.28
Ch YTD	23.24
High	1.8
High52	2.62
High52 Date	2026-01-27
High52ch	-33.1%
Low	1.74
Low52	0.71
Low52 Date	2025-06-23
Low52ch	146.48%
Ma50ch	0.57%
Premarket Change Percent	1.71
Premarket Price	$1.79
Premarket Volume	1,556
Price vs 200-day SMA	14.08%
RSI	48.5
RSI Monthly	45.03
RSI Weekly	53.43
Sharpe ratio	1.11x
Sortino ratio	1.77
Total Return	-2.26%
Tr YTD	23.24
Tr1m	4.79%
Tr1w	-2.78%
Tr3m	-18.22%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	1
Analyst Price Target Top	$10
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.27
Earnings Revenue Estimate	14,348,800x
Earnings Revenue Estimate Growth	88.82x
Operating Income	$-176.4M
Operating margin	-418.4
Price target	$7
Price Target Change	$300
Price Target Change Top	$471

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	137,493,872%
Float Percent	89.16%
Net Borrowing	-233,185,000
Shares Insiders	10.82%
Shares Institutions	34.36%
Shares Out	154,217,609
Shares Qo Q	3.56%
Shares Yo Y	2.26%
Short Float	20.34%
Short Ratio	25.04
Short Shares	18.14

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-155.5M
Average Volume	1,004,699.4x
Bv Per Share	0.5
Ch10y	-90.89
Ch1m	4.79
Ch1w	-2.78
Ch1y	84.95
Ch3m	-18.22
Ch3y	-76.29
Ch5y	-87.78
Ch6m	30.6
Change	-0.57%
Change From Open	-1.13
Close	1.76
Days Gap	0.57
Depreciation Amortization	3,924,000
Dollar Volume	1,183,140
Earnings Date	2026-05-11
Earnings Time	amc
EBIT	$-176.4M
EBITDA	$-172.5M
EPS	$1.43
F Score	5
FCF	$-138.5M
FCF EV Yield	-91.06x
FCF Per Share	$-0.9
Financing CF	-273,705,000
Fiscal Year End	December
Founded	2,010
Graham Number	4.03146
Graham Upside	130.4
Investing CF	375,087,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-09
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-09
Lynch Fair Value	$7.17
Lynch Upside	309.8
Ma150	1.64
Ma150ch	6.58%
Ma20	1.81
Ma20ch	-3.05%
Net CF	-37,131,000
Next Earnings Date	2026-05-11
Open	1.77
Optionable	Yes
Position In Range	23.08
Post Close	1.75
Postmarket Change Percent	1.14
Postmarket Price	$1.77
Ppne	4,298,000
Pre Close	1.76
Price Date	2026-05-08
Ptbv Ratio	18.27
Relative Volume	0.67x
Revenue	42,172,000x
SBC By Revenue	40.23x
Share Based Comp	16,966,000
Tr6m	30.6%
Us State	California
Volume	676,080
Z Score	-8.87

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CHRS pay a dividend?

Capital-return profile for this ticker.

Performance

CHRS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CHRS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+34.4%

Float: +89.2% of shares outstanding

Insider ownership

+10.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CHRS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.5

Neutral momentum band

Price vs 200-day MA

+14.1%

50/200-day relationship not available

Beta (5Y)

1.02

Moves roughly with the market

Sharpe ratio

1.11

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CHRS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CHRS stock rating?

Coherus Oncology, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CHRS analysis?

The full report lives at /stocks/CHRS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CHRS?

The latest report frames CHRS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CHRS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.